Cell vesicle for expressing chimeric antigen receptor as well as preparation method and application thereof

A technology of chimeric antigen receptors and cell vesicles, applied in the field of cell vesicles expressing chimeric antigen receptors and its preparation, can solve problems such as side effects, achieve the effects of reducing toxic side effects, broad application prospects, and avoiding escape

Pending Publication Date: 2021-03-19
THE FIFTH AFFILIATED HOSPITAL SUN YAT SEN UNIV
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, when using monoclonal antibody therapy, antibody-dependent cel

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cell vesicle for expressing chimeric antigen receptor as well as preparation method and application thereof
  • Cell vesicle for expressing chimeric antigen receptor as well as preparation method and application thereof
  • Cell vesicle for expressing chimeric antigen receptor as well as preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0038] Specific embodiments of the present invention will be further described below. It should be noted here that the descriptions of these embodiments are used to help understand the present invention, but are not intended to limit the present invention. In addition, the technical features involved in the various embodiments of the present invention described below may be combined with each other as long as they do not constitute a conflict with each other.

[0039] The test methods used in the following experimental examples are conventional methods unless otherwise specified; the materials and reagents used are commercially available reagents and materials unless otherwise specified.

[0040] The basic principle of the present invention is as figure 1 As shown, the present invention is used for the treatment of patients infected with the new coronavirus by loading drugs on cell vesicles expressing chimeric antigen receptors against the new coronavirus. First, construct a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of biological medicines, and discloses a cell vesicle for expressing a chimeric antigen receptor as well as a preparation method and application of the cell vesicle. The preparation method comprises the following steps: expressing a single-chain variable fragment aiming at the novel coronavirus on a cell membrane, then directly collecting or extruding cell vesicles containing expression chimeric antigen receptors, and finally loading anti-novel coronavirus such as remdesivir and the like on the cell vesicles for treating patients infected by the novel coronavirus. The prepared cell vesicle can specifically neutralize the novel coronavirus and block invasion of the novel coronavirus to cells with high expression of ACE2; meanwhile, anti-novel-coronavirus drugs such as remdesivir and the like can be transported to a novel coronavirus aggregation part in a targeted manner, so that the toxic and side effects of the drugs are reduced. Moreover, the treatment method has universality and can be used as a platform technology to be applied to treatment of other virus infections.

Description

technical field [0001] The present invention relates to the technical field of biomedicine, more specifically, to cell vesicles expressing chimeric antigen receptors and their preparation methods and applications. Background technique [0002] COVID-19 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Common symptoms include fever, cough, fatigue, shortness of breath, and loss of smell and taste. While most people have mild symptoms, some may develop acute respiratory distress syndrome (ARDS) from cytokine storms, multi-organ failure, septic shock, and blood clots. As of August 18, 2020, more than 21.8 million cases and more than 773,000 deaths have been reported in 188 countries and territories. [0003] In response to the outbreak of COVID-19, scientific researchers around the world have conducted active research on COVID-19, but no drugs or vaccines with specific indications have been approved to treat the disease. Vaccine...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N5/10C12N15/13C12N15/62C12N15/867C12N7/01C07K16/10C07K19/00A61K39/42A61K31/685A61K31/4706A61K47/46A61P31/14A61P11/00
CPCC07K16/10C07K14/7051C12N15/86C12N7/00A61K39/42A61K31/685A61K31/4706A61K47/46A61P31/14A61P11/00C07K2317/622C07K2317/76C07K2319/33C12N2740/15021C12N2740/15043A61K2300/00Y02A50/30
Inventor 黄曦朱天川肖雨晨
Owner THE FIFTH AFFILIATED HOSPITAL SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap